NCT02689427 - Enzalutamide and Paclitaxel Before Surgery in Treating Patients With Stage I-III Androgen Receptor-Positive Triple-Negative Breast Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 22, 2016

Primary Completion Date

November 15, 2023

Study Completion Date

November 15, 2023

Conditions

Invasive Breast CarcinomaStage I Breast Cancer AJCC v7Stage IA Breast Cancer AJCC v7Stage IB Breast Cancer AJCC v7Stage II Breast Cancer AJCC v6 and v7Stage IIA Breast Cancer AJCC v6 and v7Stage IIB Breast Cancer AJCC v6 and v7Stage III Breast Cancer AJCC v7Stage IIIA Breast Cancer AJCC v7Stage IIIB Breast Cancer AJCC v7Stage IIIC Breast Cancer AJCC v7Triple-Negative Breast Carcinoma

Interventions

PROCEDURE

Axillary Lymph Node Dissection

Undergo axillary lymph node dissection

DRUG

Enzalutamide

Given PO

OTHER

Laboratory Biomarker Analysis

Correlative studies

PROCEDURE

Lymph Node Biopsy

Undergo lymph node biopsy

DRUG

Paclitaxel

Given IV

PROCEDURE

Therapeutic Conventional Surgery

Undergo surgical resection of primary tumor

Trial Locations (2)

77030

M D Anderson Cancer Center, Houston

77079

MD Anderson West Houston, Houston

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER